Nordea Investment Management AB raised its stake in Dynavax Technologies Corp. (NASDAQ:DVAX) by 146.6% during the third quarter, Holdings Channel reports. The firm owned 107,305 shares of the biopharmaceutical company’s stock after buying an additional 63,792 shares during the period. Nordea Investment Management AB owned approximately 0.28% of Dynavax Technologies Corp. worth $1,126,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in DVAX. State Street Corp increased its stake in shares of Dynavax Technologies Corp. by 49.1% in the first quarter. State Street Corp now owns 1,665,452 shares of the biopharmaceutical company’s stock valued at $32,038,000 after buying an additional 548,310 shares during the period. Vanguard Group Inc. increased its position in Dynavax Technologies Corp. by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,521,695 shares of the biopharmaceutical company’s stock worth $22,187,000 after buying an additional 33,834 shares during the last quarter. BlackRock Fund Advisors increased its position in Dynavax Technologies Corp. by 6.6% in the second quarter. BlackRock Fund Advisors now owns 1,013,173 shares of the biopharmaceutical company’s stock worth $14,772,000 after buying an additional 62,391 shares during the last quarter. Blair William & Co. IL increased its position in Dynavax Technologies Corp. by 17.9% in the second quarter. Blair William & Co. IL now owns 377,772 shares of the biopharmaceutical company’s stock worth $4,607,000 after buying an additional 57,225 shares during the last quarter. Finally, Tekla Capital Management LLC increased its position in Dynavax Technologies Corp. by 43.2% in the second quarter. Tekla Capital Management LLC now owns 345,050 shares of the biopharmaceutical company’s stock worth $5,031,000 after buying an additional 104,100 shares during the last quarter. Institutional investors own 86.80% of the company’s stock.
Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) traded up 3.09% on Friday, reaching $5.00. The company had a trading volume of 658,110 shares. Dynavax Technologies Corp. has a 12 month low of $3.20 and a 12 month high of $29.86. The stock’s market cap is $192.64 million. The stock has a 50-day moving average price of $8.88 and a 200-day moving average price of $13.14.
Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.15. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $2.44 million. Dynavax Technologies Corp. had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. The firm’s quarterly revenue was down 83.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.82) earnings per share. Analysts predict that Dynavax Technologies Corp. will post ($3.21) earnings per share for the current fiscal year.
A number of research firms recently issued reports on DVAX. Zacks Investment Research upgraded Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a report on Monday, September 5th. Cowen and Company reiterated an “outperform” rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a report on Tuesday, September 6th. Finally, RBC Capital Markets set a $4.00 price objective on Dynavax Technologies Corp. and gave the stock a “hold” rating in a report on Monday, November 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $20.14.
Dynavax Technologies Corp. Company Profile
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).